Literature DB >> 3072556

Disposition of detirelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and monkeys.

R L Chan1, W Ho, A S Webb, J A LaFargue, C A Nerenberg.   

Abstract

The disposition of detirelix, a potent luteinizing hormone-releasing hormone (LHRH) antagonist, was studied in rats and monkeys. After a single 300-microgram/kg intravenous dose in rats, the plasma elimination t1/2 was 1.6 hr and the plasma clearance was 3.3 ml/min/kg. In the monkey, the mean t1/2 and plasma clearance were 7.1 hr and 1.3 ml/min/kg, respectively, after an 80-microgram/kg intravenous dose. Long plasma t1/2 values of 18.7 and 31.6 hr were observed after single 0.2- and 1.0-mg/kg subcutaneous doses in the monkey, suggesting the possibility of subcutaneous depot formation at the injection site. Biliary excretion was the predominant route of elimination of detirelix in both species. Less than 10% of the detirelix was excreted renally. A major metabolite, isolated from the rat bile, was the 1-4 tetrapeptide fragment of detirelix. This metabolite was formed by enzymatic hydrolysis of the Ser4-Tyr5 bond, one of the only two peptide bonds in detirelix not containing a D-amino acid.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3072556     DOI: 10.1023/a:1015947325283

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

1.  Effects of an LH-releasing hormone antagonist on the secretion of LH, FSH, prolactin and ovarian steroids at different stages of the luteal phase in the stumptailed macaque (Macaca arctoides).

Authors:  H M Fraser; M Abbott; N C Laird; A S McNeilly; J J Nestor; B H Vickery
Journal:  J Endocrinol       Date:  1986-10       Impact factor: 4.286

2.  Suppression of plasma gonadotropins and testosterone in adult male monkeys (Macaca fascicularis) by a potent inhibitory analog of gonadotropin-releasing hormone.

Authors:  L A Adams; W J Bremner; J J Nestor; B H Vickery; R A Steiner
Journal:  J Clin Endocrinol Metab       Date:  1986-01       Impact factor: 5.958

3.  Effects of gonadotropin releasing hormone agonists and antagonists on reproductive functions.

Authors:  C Rivier; W Vale; J Rivier
Journal:  J Med Chem       Date:  1983-11       Impact factor: 7.446

4.  Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men.

Authors:  S N Pavlou; G B Wakefield; D P Island; P G Hoffman; M E LePage; R L Chan; C A Nerenberg; W J Kovacs
Journal:  J Clin Endocrinol Metab       Date:  1987-05       Impact factor: 5.958

5.  Disposition of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in rats and rhesus monkeys.

Authors:  N I Chu; R L Chan; K M Hama; M D Chaplin
Journal:  Drug Metab Dispos       Date:  1985 Sep-Oct       Impact factor: 3.922

6.  Identification of major urinary metabolites of nafarelin acetate, a potent agonist of luteinizing hormone-releasing hormone, in the rhesus monkey.

Authors:  R L Chan; M D Chaplin
Journal:  Drug Metab Dispos       Date:  1985 Sep-Oct       Impact factor: 3.922

7.  GnRH-receptors of rat pituitary is a glycoprotein: differential effect of neuraminidase and lectins on agonists and antagonists binding.

Authors:  E Hazum
Journal:  Mol Cell Endocrinol       Date:  1982-04       Impact factor: 4.102

8.  A complete separation of dimethylaminoazobenzenesulphonyl-amino acids. Amino acid analysis with low nanogram amounts of polypeptide with dimethylaminoazobenzenesulphonyl chloride.

Authors:  J Y Chang; R Knecht; D G Braun
Journal:  Biochem J       Date:  1982-06-01       Impact factor: 3.857

9.  The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients.

Authors:  T Kobayashi; S Sawano; T Itoh; K Kosaka; H Hirayama; Y Kasuya
Journal:  Diabetes       Date:  1983-04       Impact factor: 9.461

10.  Synthesis and biological activity of some very hydrophobic superagonist analogues of luteinizing hormone-releasing hormone.

Authors:  J J Nestor; T L Ho; R A Simpson; B L Horner; G H Jones; G I McRae; B H Vickery
Journal:  J Med Chem       Date:  1982-07       Impact factor: 7.446

View more
  3 in total

1.  Population pharmacokinetic/pharmacodynamic modeling of cetrorelix, a novel LH-RH antagonist, and testosterone in rats and dogs.

Authors:  M Schwahn; N V Nagaraja; H Derendorf
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

2.  Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep.

Authors:  H Schreier; K J McNicol; D B Bennett; Z Teitelbaum; H Derendorf
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

3.  Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly anesthetized dog.

Authors:  D B Bennett; E Tyson; C A Nerenberg; S Mah; J S de Groot; Z Teitelbaum
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.